NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis $8.11 -0.02 (-0.25%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$8.11 +0.00 (+0.02%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sight Sciences Stock (NASDAQ:SGHT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sight Sciences alerts:Sign Up Key Stats Today's Range$7.95▼$8.2250-Day Range$4.70▼$8.5552-Week Range$3.19▼$9.24Volume88,804 shsAverage Volume170,643 shsMarket Capitalization$446.78 millionP/E RatioN/ADividend YieldN/APrice Target$7.88Consensus RatingModerate Buy Company Overview Sight Sciences, Inc. is a medical technology company focused on developing and commercializing treatments for common eye diseases. The company’s products are designed to address glaucoma and dry eye disease, with an emphasis on minimally invasive procedures and technologies intended for use by eye-care professionals. Its glaucoma portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to help reduce intraocular pressure by improving the eye’s natural fluid outflow pathways. Sight Sciences also offers the TearCare System, which is designed to treat meibomian gland dysfunction, a leading cause of evaporative dry eye disease, by applying localized thermal therapy to the eyelids. Sight Sciences markets its products primarily through ophthalmology and optometry channels in the United States and has expanded its commercial presence into select international markets. The company is headquartered in Menlo Park, California, and its shares trade on the Nasdaq under the symbol SGHT.AI Generated. May Contain Errors. Read More Sight Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSGHT MarketRank™: Sight Sciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 779th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingModerate Buy Consensus RatingSight Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Sight Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageSight Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Sight Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($0.52) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -14.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -14.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 6.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sight Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.19% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Sight Sciences has recently increased by 38.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.21 News SentimentSight Sciences has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sight Sciences this week, compared to 3 articles on an average week. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $318,827.00 in company stock.Percentage Held by Insiders30.40% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sight Sciences' insider trading history. Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGHT Stock News HeadlinesComparing MiniMed Group (NASDAQ:MMED) & Sight Sciences (NASDAQ:SGHT)1 hour ago | americanbankingnews.comSight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15 at 12:00 PM | seekingalpha.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio. | Stansberry Research (Ad)Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15September 1, 2026 | globenewswire.comSight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye DiseaseAugust 19, 2026 | finanznachrichten.deSight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye DiseaseAugust 19, 2026 | quiverquant.comQTearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye DiseaseAugust 19, 2026 | globenewswire.comSight Sciences Earnings Call Shows Growth And DisciplineAugust 17, 2026 | tipranks.comSee More Headlines SGHT Stock Analysis - Frequently Asked Questions How have SGHT shares performed this year? Sight Sciences' stock was trading at $7.93 at the beginning of 2026. Since then, SGHT stock has increased by 2.3% and is now trading at $8.11. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) issued its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.10. The company earned $23.39 million during the quarter, compared to analysts' expectations of $21.72 million. Sight Sciences had a negative net margin of 35.69% and a negative trailing twelve-month return on equity of 43.39%. Read the conference call transcript. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $235 million in an initial public offering (IPO) on Wednesday, July 14th 2021. The company issued 10,000,000 shares at a price of $23.00-$24.00 per share. Who are Sight Sciences' major shareholders? Sight Sciences' top institutional shareholders include BlackRock Inc. (5.67%), Squarepoint Ops LLC (0.40%), GSA Capital Partners LLP (0.31%) and Bank of America Corp DE (0.17%). Insiders that own company stock include Paul Badawi, D1 Capital Partners LP, David Badawi, Staffan Encrantz, Matthew Link, Alison Bauerlein, Jeremy B Hayden, Brenton Taylor, Sam Boong Park, James Rodberg and Manohar K Raheja. View institutional ownership trends. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sight Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sight Sciences investors own include American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/05/2026Today9/15/2026Morgan Stanley 24th Annual Global Healthcare Conference9/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:SGHT CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees186Year Founded2011Price Target and Rating Average Price Target for Sight Sciences$7.88 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside-2.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.43 million Net Margins-35.69% Pretax Margin-35.73% Return on Equity-43.39% Return on Assets-22.86% Debt Debt-to-Equity Ratio0.58 Current Ratio4.95 Quick Ratio4.67 Sales & Book Value Annual Sales$77.36 million Price / Sales5.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book6.70Miscellaneous Outstanding Shares55,090,000Free Float38,341,000Market Cap$446.78 million OptionableOptionable Beta2.50 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:SGHT) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
